{"organizations": [], "uuid": "f49f2911eb120d75f7260c95b26fd62645de03fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180430.html", "section_title": "Archive News &amp; Video for Monday, 30 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-keryx-biopharmaceuticals-sees-tota/brief-keryx-biopharmaceuticals-sees-total-revenue-for-qtr-ended-march-31-2018-between-21-0-mln-and-22-5-mln-idUSFWN1S70XR", "country": "US", "domain_rank": 408, "title": "BRIEF-Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.008, "site_type": "news", "published": "2018-04-30T20:40:00.000+03:00", "replies_count": 0, "uuid": "f49f2911eb120d75f7260c95b26fd62645de03fc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-keryx-biopharmaceuticals-sees-tota/brief-keryx-biopharmaceuticals-sees-total-revenue-for-qtr-ended-march-31-2018-between-21-0-mln-and-22-5-mln-idUSFWN1S70XR", "ord_in_thread": 0, "title": "BRIEF-Keryx Biopharmaceuticals Sees Total Revenue For Qtr Ended March 31, 2018 Between $21.0 Mln And $22.5 Mln", "locations": [], "entities": {"persons": [{"name": "jodie morrison", "sentiment": "none"}, {"name": "gregory madison", "sentiment": "none"}], "locations": [], "organizations": [{"name": "brief-keryx biopharmaceuticals", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "keryx biopharmaceuticals inc", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 30 (Reuters) - Keryx Biopharmaceuticals Inc:\n* KERYX BIOPHARMACEUTICALS SEES TOTAL REVENUE FOR QUARTER ENDED MARCH 31, 2018 OF BETWEEN $21.0 MILLION AND $22.5 MILLION - SEC FILING\n* SAYS CEO AND PRESIDENT GREGORY MADISON RESIGNED * APPOINTED JODIE MORRISON AS INTERIM CHIEF EXECUTIVE OFFICER\n* REDUCED SIZE OF BOARD FROM EIGHT DIRECTORS TO SEVEN DIRECTORS Source text: [ bit.ly/2w0gKQT ] Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://bit.ly/2w0gKQT", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "https://www.youtube.com/user/ReutersVideo", "https://instagram.com/reuters/"], "published": "2018-04-30T20:40:00.000+03:00", "crawled": "2018-05-01T20:28:31.004+03:00", "highlightTitle": ""}